Recombinant Human Interleukine-1beta usage for acute radiation sickness of severe degree treatment at canines
2008
Rozhdestvenskij, L.M. | Korovkina, Eh.P. | Deshevij, Yu. B.
The therapeutic efficacy of Recombinant human interleukinr-1в (Betaleukine) was studied as a remedy for anti-radiation therapy of acute radiation sickness (ARS) in experimental dogs. Dogs were irradiated totally in doses above LD 95/45. Betaleukine was administered subcutaneously in a dose of 1-2 ml in 15 min-2 h after irradiation, to control animals – 0.9% NaCl solution. All the dogs including the control ones received intramuscularly in acute period 8-24 days after irradiation ampicillin (0.25 g) and gentamicin (1.0 ml) twice a day 8 h apart. As was found, the administration of only one Betaleukine in doses of 0.1 and 1 microg/kg revealed no difference in their anti-radiation efficacy. This proved wider therapeutic efficacy of Betaleukine. Betaleukine increased 45-day survival by 31% under a dose of 4.0 Gy and by 25% under 4.4 Gy. All the control dogs died. Its positive effect on the level of blood forming elements was observed during their maximum reduction and the beginning of restoration at days 17-21. The most pronounced differences were found among lymphocytes and monocytes at days 14 and 21 in dogs irradiated by a dose of 4.0 Gy compared with control. It is concluded that Betaleukine effects mainly on hemopoietic stem cells preventing death of a stem cell part or intensifying its proliferation. Being an activating factor, Betaleukine results in accelerated recovery of hemopoiesis and an increase in the survivability of irradiated animals. It is recommended to use as a remedy for urgent pathogenic therapy at radiation human accidents
显示更多 [+] 显示较少 [-]